IP Verse

Glp-1 Compositions And Uses Thereof

EP3474820

NOVO NORDISK A/S
Application Number
EP18756449A
Filing Date
Aug 24, 2018
Status
Granted And Under Opposition
Jan 5, 2024
Grant Date
Feb 7, 2024
External Links
Slate, Register

Biblio Summary

The patent EP3474820B1 was granted on Feb 7, 2024 by Novo Nordisk A/S The patent is currently Granted And Under Opposition.

Oppositions Filed by other Companies on the Patent

The table below shows 8 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ADALVO LTD.Nov 7, 2024ADMISSIBLE
ELKINGTON AND FIFE LLPNov 7, 2024ADMISSIBLE
GENERICS (U.K.) LIMITEDNov 7, 2024ADMISSIBLE
SANDOZ AGNov 7, 2024ADMISSIBLE
STRAWMAN LIMITEDNov 7, 2024ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Nov 7, 2024ADMISSIBLE
KRAUS & LEDERER PARTGMBBNov 6, 2024ADMISSIBLE
MAIWALD GMBHNov 6, 2024ADMISSIBLE

More Opposed Patents of Novo Nordisk A/S

The table below shows the patents of Novo Nordisk A/S that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3250191Tablets Comprising Glp-1 Agonist And Enteric CoatingJan 17, 20241
EP3488857Compositions Of Glp-1 Peptides And Preparation ThereofOct 4, 20235
EP3542790Compositions Comprising A Delivery Agent And Preparation ThereofSep 13, 20237

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.

  • Date

    Description

  • Get instant alerts for new documents